Hormonal
Inadvertent exposure to GLP-1 receptor agonists during pregnancy does not appear to pose a significant teratogenic risk, with congenital abnormality rates in exposed pregnancies being lower than or comparable to placebo groups.
If you took a GLP-1 medication (like Ozempic or Wegovy) before knowing you were pregnant, current data from clinical trials does not show an increased risk of birth defects compared to women who did not take these medications. You should stop the medication as soon as you know you are pregnant and consult your doctor for standard prenatal care.
The incidence of congenital abnormalities in humans appears relatively low following Glucagon-like peptide-1 receptor agonist use during pregnancy.
Why this rating
Data is aggregated from regulatory clinical trials but limited by small sample sizes of unplanned pregnancies and lack of long-term follow-up for many cases.
Source
Glucagon‐like peptide 1 ( <scp>GLP</scp> ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
Claire Parker et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16437
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →